Kato A, Naitoh I, Naiki-Ito A, Hayashi K, et al. Class III beta-Tubulin Expression Is of Value in Selecting nab-Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. Pancreas 2022 Jun 13. pii: 00006676-990000000-00009.
PMID: 35695793